申请人:Kambe Tohru
公开号:US20120122964A1
公开(公告)日:2012-05-17
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
由一种由通式(I)表示的化合物(其中每个基团的定义如规范中所述),其盐、溶剂合物或前药具有强大且持续的降低眼压活性,并且对眼睛没有副作用,如眼刺激性(充血、角膜混浊等)、房水蛋白上升等,具有高安全性,并可作为预防和/或治疗青光眼等的优秀药物。